Fusion IP signs agreement with pharmaceutical company

Fusion IP, which commercialises university research, has signed an agreement with a pharmaceutical company utilising intellectual property out of the University of Sheffield, for the development of a known drug.

The agreement, which is worth over $500m per year is royalty-based, with limited milestone payments, will cover most of Fusion's net annual overheads.

The drug is already being marketed for a different treatment and as such the probability of a successful launch is considered to be high, the firm said.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

The drug is currently at the second stage of development and is expected to make its first sales in 2015/16, with royalties to Fusion expected to peak at £1m per year.

Dr Andrew Tingey, Head of Licensing at Fusion, said: "This is an excellent licence for Fusion and demonstrates the value that can be unlocked through licensing the non spin-out opportunities within the Fusion pipeline."

The share price rose 10.39% to 42.5p by 12:40.

NR